US equities |
SPCX $167.10 ▲+5.12% NVDA $237.13 ▲+1.36% MU $1,066.84 ▼-0.75% TSLA $375.43 ▲+1.31% MSFT $526.13 ▲+1.66% INTC $116.77 ▼-2.15% SNDK $1,719.09 ▼-0.05% META $742.62 ▲+2.00%
FinancialContent

Articles published by AgomAb Therapeutics N.V.

News headline image
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
From AgomAb Therapeutics N.V.
Via GlobeNewswire
Tickers AGMB